RS62829B1 - Kombinovana terapija za lečenje maligniteta - Google Patents

Kombinovana terapija za lečenje maligniteta

Info

Publication number
RS62829B1
RS62829B1 RS20211449A RSP20211449A RS62829B1 RS 62829 B1 RS62829 B1 RS 62829B1 RS 20211449 A RS20211449 A RS 20211449A RS P20211449 A RSP20211449 A RS P20211449A RS 62829 B1 RS62829 B1 RS 62829B1
Authority
RS
Serbia
Prior art keywords
compound
technical solution
azacitidine
day
idh1
Prior art date
Application number
RS20211449A
Other languages
English (en)
Serbian (sr)
Inventor
Samuel V Agresta
Krishnan Viswanadhan
Jorge Dimartino
Vivek Saroj Kumar Chopra
Kyle J Macbeth
Robert Douglas Knight
Laurie Kenvin
Qiang Xu
Original Assignee
Servier Lab
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Celgene Corp filed Critical Servier Lab
Publication of RS62829B1 publication Critical patent/RS62829B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20211449A 2015-10-15 2016-10-14 Kombinovana terapija za lečenje maligniteta RS62829B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242282P 2015-10-15 2015-10-15
PCT/US2016/057042 WO2017066571A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies
EP16856278.3A EP3362066B1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (1)

Publication Number Publication Date
RS62829B1 true RS62829B1 (sr) 2022-02-28

Family

ID=58518368

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211449A RS62829B1 (sr) 2015-10-15 2016-10-14 Kombinovana terapija za lečenje maligniteta

Country Status (28)

Country Link
US (2) US10653710B2 (enExample)
EP (1) EP3362066B1 (enExample)
JP (1) JP7033061B2 (enExample)
KR (1) KR102699521B1 (enExample)
CN (1) CN108697698B (enExample)
AU (1) AU2016338557B2 (enExample)
CA (1) CA3002068A1 (enExample)
CL (1) CL2018000943A1 (enExample)
CY (1) CY1124951T1 (enExample)
DK (1) DK3362066T3 (enExample)
EA (1) EA039829B1 (enExample)
ES (1) ES2897959T3 (enExample)
HR (1) HRP20211790T1 (enExample)
HU (1) HUE057263T2 (enExample)
IL (1) IL258685B (enExample)
LT (1) LT3362066T (enExample)
MA (1) MA43000B1 (enExample)
MD (1) MD3362066T2 (enExample)
MX (1) MX386735B (enExample)
PL (1) PL3362066T3 (enExample)
PT (1) PT3362066T (enExample)
RS (1) RS62829B1 (enExample)
SG (2) SG10202111435UA (enExample)
SI (1) SI3362066T1 (enExample)
SM (1) SMT202100658T1 (enExample)
UA (1) UA123400C2 (enExample)
WO (1) WO2017066571A1 (enExample)
ZA (1) ZA201803166B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
KR20250126877A (ko) 2015-10-15 2025-08-25 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
ES2897959T3 (es) * 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
CN111163776A (zh) * 2017-06-12 2020-05-15 安吉奥斯医药品有限公司 使用组合疗法治疗脑肿瘤的方法
EP3661559A1 (en) * 2017-08-01 2020-06-10 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Combination of midh1 inhibitors and dna hypomethylating agents (hma)
WO2019099653A1 (en) * 2017-11-16 2019-05-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
BR112021000156A2 (pt) * 2018-07-06 2021-04-06 Agios Pharmaceuticals, Inc. Formas de ivosidenib e composições farmacêuticas
CN109224061B (zh) * 2018-11-16 2022-01-07 上海市肺科医院 化合物ag120或其药学上可接受的盐在制备预防或治疗结核病的药物中的用途
JP2022537384A (ja) 2019-06-20 2022-08-25 セルジーン コーポレーション ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
US12168005B2 (en) 2019-10-07 2024-12-17 University Hospitals Cleveland Medical Center Methods for treating wild type isocitrate dehydrogenase 1 cancers
GB2590601B (en) * 2019-11-13 2024-01-31 Thermo Fisher Scient Bremen Gmbh Method of mass spectrometry
BR112022017394A2 (pt) 2020-03-23 2022-10-18 Lilly Co Eli Terapia de combinação com um inibidor de idh mutante

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
DE1252823B (enExample) 1963-02-15
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
BE793501A (fr) 1971-12-31 1973-06-29 Ciba Geigy Composes heterocycliques et produits phytopharmaceutiques qui en contiennent
CH606334A5 (enExample) 1974-06-21 1978-10-31 Ciba Geigy Ag
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
EP0385237B1 (en) 1989-03-03 1994-06-29 Dainippon Pharmaceutical Co., Ltd. 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
JPH05140126A (ja) 1991-11-26 1993-06-08 Hokko Chem Ind Co Ltd トリアゾール誘導体および除草剤
EP0629622B1 (en) 1992-02-28 1998-11-11 Zenyaku Kogyo Kabushikikaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
AU1608397A (en) 1996-02-02 1997-08-22 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
CA2271744A1 (en) 1996-11-14 1998-05-22 Isao Hashiba Cyanoethylmelamine derivatives and process for producing the same
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
IL136737A0 (en) 1997-12-22 2001-06-14 Bayer Ag Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
WO2000002864A1 (en) 1998-07-10 2000-01-20 Martens Juergen Precusors for pna-monomers
CA2338665C (en) 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
US6274620B1 (en) 1999-06-07 2001-08-14 Biochem Pharma Inc. Thiophene integrin inhibitors
ATE309207T1 (de) 1999-08-27 2005-11-15 Sugen Inc Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU8066701A (en) 2000-07-20 2002-02-05 Neurogen Corp Capsaicin receptor ligands
JP4113323B2 (ja) 2000-08-07 2008-07-09 富士フイルム株式会社 アゾ色素及びそれを含むインクジェット記録用インク、並びにインクジェット記録方法
US6525091B2 (en) 2001-03-07 2003-02-25 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
KR20090019894A (ko) 2001-06-11 2009-02-25 바이오비트럼 에이비(피유비엘) 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형 당뇨병 치료용 약제로서의 이들의 사용 방법
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
DE60238066D1 (de) 2001-08-17 2010-12-02 Basf Se Triazinderivate und deren verwendung als sonnenschutzmittel
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
JP2004083610A (ja) 2002-08-22 2004-03-18 Fuji Photo Film Co Ltd インクセット、インクカートリッジ、記録方法、プリンター及び記録物
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
ES2373947T3 (es) 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
EP1618090A1 (en) 2003-04-11 2006-01-25 Novo Nordisk A/S 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
EP1482418A1 (en) 2003-05-28 2004-12-01 Sap Ag A data processing method and system
EP1663211B1 (en) 2003-08-06 2010-01-20 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
US7582645B2 (en) 2003-10-10 2009-09-01 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
EP1708712A1 (en) 2003-12-24 2006-10-11 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
JP2005264016A (ja) 2004-03-19 2005-09-29 Fuji Photo Film Co Ltd インクジェット記録用インク、インクセット及びインクジェット記録方法
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
GB0412526D0 (en) 2004-06-05 2004-07-14 Leuven K U Res & Dev Type 2 diabetes
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AU2005286593A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
CA2594708A1 (en) 2005-01-25 2006-08-03 Astrazeneca Ab Chemical compounds
US7811800B2 (en) 2005-04-11 2010-10-12 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
WO2007023186A1 (en) 2005-08-26 2007-03-01 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
WO2008036835A2 (en) 2006-09-20 2008-03-27 Reddy Us Therapeutics Methods and compositions for upregulation of peroxiredoxin activity
US20080109846A1 (en) 2006-10-23 2008-05-08 Ewertz C Christian System and method for audiovisual content playback
EP2086329B1 (en) 2006-10-26 2014-07-23 The Arizona Board of Regents on behalf of the University of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008070661A1 (en) 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
NZ578180A (en) 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
CA2672893C (en) 2006-12-15 2016-02-23 Abraxis Bioscience, Inc. Triazine derivatives and their therapeutical applications
US8258295B2 (en) 2007-04-30 2012-09-04 Prometic Biosciences Inc. Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives
JP2010529193A (ja) 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
TW200906818A (en) 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
EA201070451A1 (ru) 2007-10-10 2010-10-29 Такеда Фармасьютикал Компани Лимитед Амидные соединения
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
ES2774226T3 (es) * 2008-05-15 2020-07-17 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
ES2755139T3 (es) 2008-09-03 2020-04-21 Univ Johns Hopkins Alteraciones genéticas en la citrato deshidrogenasa y otros genes en gliomas malignos
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
EP2370417A2 (en) 2008-11-21 2011-10-05 Millennium Pharmaceuticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
PT2394999E (pt) 2009-02-06 2014-05-02 Nippon Shinyaku Co Ltd Derivado de aminopirazina e medicamento correspondente
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
DK2427441T3 (en) 2009-05-04 2017-03-20 Agios Pharmaceuticals Inc PKM2 Activators for use in the treatment of cancer
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
EP2440050A4 (en) 2009-06-08 2013-04-03 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
KR20120026611A (ko) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 헷지호그 신호전달의 피리딜-트리아진 억제제
AU2010258825B2 (en) 2009-06-09 2014-08-21 Nantbio, Inc. Ureidophenyl substituted triazine derivatives and their therapeutical applications
CR20170071A (es) 2009-06-29 2017-03-28 Agios Pharmaceuticals Inc Compuestos terapeuticos y composiciones
US20120101587A1 (en) 2009-07-10 2012-04-26 Milux Holding Sa Knee joint device and method
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
US20120189670A1 (en) 2009-09-14 2012-07-26 Kirkpatrick D Lynn Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
IN2012DN03312A (enExample) 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
EP2509600B1 (en) 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
NZ578968A (en) 2010-02-10 2011-03-31 Allans Sheetmetal And Engineering Services Fuel feed system for a pellet fire
US20130197106A1 (en) 2010-04-01 2013-08-01 Agios Pharmaceuticals, Inc Methods of identifying a candidate compound
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
WO2012009678A1 (en) 2010-07-16 2012-01-19 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their method of use
TWI557123B (zh) 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
WO2012078288A2 (en) 2010-11-08 2012-06-14 Washington University Methods of determining risk of adverse outcomes in acute myeloid leukemia
SG10201601507YA (en) 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012173682A2 (en) 2011-03-29 2012-12-20 The Broad Institute, Inc. Compounds and methods for the treatment of isocitrate dehydrognase related diseases
CA2834692A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
WO2012170284A1 (en) * 2011-06-06 2012-12-13 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
AU2012280725B2 (en) 2011-07-07 2017-02-02 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
US9167820B2 (en) 2011-07-22 2015-10-27 University Of Louisville Research Foundation, Inc. Anti-biofilm compounds
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
KR101893112B1 (ko) 2012-01-06 2018-08-30 아지오스 파마슈티컬스 아이엔씨. 치료학적으로 활성인 화합물 및 이의 이용 방법
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CA2860858A1 (en) 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP2634259A1 (en) 2012-03-01 2013-09-04 Deutsches Krebsforschungszentrum Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG)
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
AU2013232379A1 (en) 2012-03-12 2014-09-25 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
WO2014015422A1 (en) 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015127172A1 (en) 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
US20170007661A1 (en) 2014-03-14 2017-01-12 Agios Pharmaceuticals, Inc Pharmaceutical compositions of therapeutically active compounds
ES2897959T3 (es) 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
KR20250126877A (ko) 2015-10-15 2025-08-25 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
CA3007363A1 (en) 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
US10137130B2 (en) 2016-02-26 2018-11-27 Celgene Corporation Methods of treatment of malignancies
CA3036384A1 (en) * 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors

Also Published As

Publication number Publication date
UA123400C2 (uk) 2021-03-31
JP2018536636A (ja) 2018-12-13
ZA201803166B (en) 2022-12-21
EA039829B1 (ru) 2022-03-17
CN108697698A (zh) 2018-10-23
BR112018007656A2 (pt) 2018-11-06
AU2016338557A1 (en) 2018-05-31
MD3362066T2 (ro) 2022-08-31
MA43000B1 (fr) 2021-11-30
MA43000A (fr) 2021-05-12
PT3362066T (pt) 2021-11-16
EP3362066A1 (en) 2018-08-22
PL3362066T3 (pl) 2022-05-02
WO2017066571A1 (en) 2017-04-20
ES2897959T3 (es) 2022-03-03
JP7033061B2 (ja) 2022-03-09
CN108697698B (zh) 2021-12-03
MX386735B (es) 2025-03-19
EP3362066B1 (en) 2021-10-06
SG11201803091PA (en) 2018-05-30
BR122024000250A2 (pt) 2024-02-27
EA201890957A1 (ru) 2018-09-28
SMT202100658T1 (it) 2022-03-21
LT3362066T (lt) 2022-02-10
SG10202111435UA (en) 2021-12-30
HRP20211790T1 (hr) 2022-03-04
CA3002068A1 (en) 2017-04-20
MX2018004586A (es) 2018-08-16
KR102699521B1 (ko) 2024-08-26
US20180296583A1 (en) 2018-10-18
US20200405737A1 (en) 2020-12-31
SI3362066T1 (sl) 2022-04-29
NZ742480A (en) 2024-08-30
HUE057263T2 (hu) 2022-04-28
IL258685A (en) 2018-06-28
EP3362066A4 (en) 2019-06-19
KR20180067658A (ko) 2018-06-20
IL258685B (en) 2022-03-01
DK3362066T3 (da) 2021-11-22
CY1124951T1 (el) 2023-01-05
AU2016338557B2 (en) 2022-05-26
US10653710B2 (en) 2020-05-19
CL2018000943A1 (es) 2018-10-12

Similar Documents

Publication Publication Date Title
AU2016338557B2 (en) Combination therapy for treating malignancies
AU2016363011B2 (en) Methods of treatment of malignancies
EP3419594B1 (en) Ivosidenib for use in the treatment of relapsed/refractory aml
KR102701893B1 (ko) 악성종양을 치료하기 위한 조합 요법
EP3362065B1 (en) Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
HK1259245B (en) Combination therapy for treating malignancies
HK1259245A1 (en) Combination therapy for treating malignancies
BR122024020713A2 (pt) Uso de composto em terapia de combinação para tratamento de doenças malignas
BR122024000250B1 (pt) Uso de um inibidor de desidrogenase isocitrato1 (IDH1) mutante e um agente desmetilante
HK40114599A (en) Combination therapy for treating malignancies
BR112018007656B1 (pt) Uso do inibidor de isocitrato desidrogenase 1 mutante (IDH1) e azacitidina
HK40002835A (en) Ivosidenib for use in the treatment of relapsed/refractory aml
HK40002835B (en) Ivosidenib for use in the treatment of relapsed/refractory aml